Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 13Expanded_access 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Recurrence 1

Interventions

3-Iodobenzylguanidine 3talquetamab 2ibrutinib 2zanubrutinib 1vorasidenib 1sugemalimab 1revumenib 1pomalidomide 1loncastuximab tesirine 1fludarabine phosphate 1fludarabine 1denileukin diftitox 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Whole-Body Irradiation 1Tacrolimus 1Panobinostat 1Mycophenolic Acid 1Immunotherapy, Adoptive 1Cytarabine 1Cyclophosphamide 1Cord Blood Stem Cell Transplantation 1Busulfan 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Recurrence × Panobinostat × Clear all
NCT02568943 2020-04-08

An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

Novartis

No longer available
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡